

COMPLETE IF KNOWN

Application Number	10/582,621
Filing Date	June 12, 2006
First Named Inventor	Pallaoro et al.
Group Art Unit	-- 1633
Examiner Name	-- Marvin

A circular black ink stamp from the Patent & Trademark Office. The text "PATENT & TRADEMARK OFFICE" is curved along the bottom inner edge. The date "MAY 18 2007" is stamped in the center. The top inner edge of the stamp is partially obscured by the text "154B E 1000".

Sheet 1 of 4

Attorney Docket Number	ITR0053YP
------------------------	-----------

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		5741657		Tsien et al.	04/21/1998
		5807692		Kinzler et al.	09/15/1998
		5871968		Kinzler et al.	02/16/1999
		5955604		Tsien et al.	09/21/1999
		5993845		Geerts et al.	11/30/1999
		6068987		Dulski et al.	05/30/2000
		6291162		Tsien et al.	09/18/2001
		6387673		Evans et al.	05/14/2002
		6472205		Tsien et al.	10/29/2002
		6511990		Breslow et al.	01/28/2003
		6541661		Delorme et al.	04/01/2003
		6544957		Kern et al.	04/08/2003
		6638530		Ishibashi et al.	10/28/2003
					duplicate refer

duplicate references

[illegible]

/Maria Marvich/

Date
Considered

10/25/2008

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/582,621	
			Filing Date	June 12, 2006	
			First Named Inventor	Pallaoro et al.	
			Group Art Unit	--	
			Examiner Name	--	
Sheet	2	of	4	Attorney Docket Number	ITR0053YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/M.M./	AA	Goodwin et al., Molecular Pharmacology, Vol. 56 (1999), pp. 1329-1339, "The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 ..."
/M.M./	AB	Xing et al., J. Receptor & Signal Transduction Research, Vol. 20 (2000), pp. 189-210, "A fluorescent reporter assay for the detection of ligands acting through G1 protein-coupled receptors"
	AC	Kramer et al., Trends in Endocrinol & Metab., Vol. 12 (2001), pp. 294-300, "Histone deacetylase as a therapeutic target"
	AD	Colletti et al., Bioorg. & Med. Chem. Letters, Vol. 11 (2001), pp. 113-117, "Broad spectrum antiprotozoal agents that inhibit histone deacetylase: ..."
	AE	Archer et al., Curr. Opin. in Genetics & Develop., Vol. 9 (1999), p. 171-174, "Histone acetylation and cancer"
	AF	Colletti et al., Bioorg. & Med. Chem. Letters, Vol. 11 (2001), pp. 107-111, "Broad spectrum antiprotozoal agents that inhibit histone deacetylase: ..."
	AG	Sowa et al., Biochem. & Biophys. Res. Comm., Vol. 241 (1997), pp. 142-150, "Histone deacetylase inhibitor activates the WAF1/Cip1 gene ..."
	AH	Galarneau et al., Nature Biotech., Vol. 20 (2002), pp. 619-622, "Beta-lactamase protein fragment complementation assays in vivo and in vitro ..."
	AI	Egawa et al., Biol. Pharm. Bull., Vol. 21 (1998), pp. 899-904, "Identification of active substances from Streptomyces culture ..."
/M.M./	AJ	Hustert et al., Drug Metab. & Disposition, Vol. 29 (2001), pp. 1454-1459, "Natural protein variants of pregnane X receptor with altered transactivation ..."
	AK	Ziolkarnik et al., Science, Vol. 279 (1998), p. 84-88, "Quantitation of transcription and clonal selection of single living cells ..."
	AL	Vigushin et al., Anti-Cancer Drugs, Vol. 13 (2002), pp. 1-13, "Histone deacetylase inhibitors in cancer treatment"
	AM	Nere et al., Anal. Biochem., Vol. 267 (1999), pp. 390-396, "Development of a scintillation proximity assay for histone deacetylase using a biotinylated peptide ..."
	AN	Huang et al., Oncogene, Vol. 19 (2000), pp. 5712-5719, "Activation of the p21 WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor ..."
	AO	Grozinger et al., Chem. & Biol., Vol. 9 (2002), pp. 3-16, "Deacetylase Enzymes: Biological functions and the use of small-molecule inhibitors"

Examiner Signature	/Maria Marvich/	Date Considered	10/25/2008
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO			COMPLETE IF KNOWN		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Application Number	10/582,621	
			Filing Date	June 12, 2006	
			First Named Inventor	Pallaoro et al.	
			Group Art Unit	--	
			Examiner Name	--	
Sheet	3	of	4	Attorney Docket Number	ITR0053YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/M.M./	AP	Goodwin et al., Molec. Pharmacol., Vol. 62 (2002), pp. 359-365, "Transcriptional regulation of the human CYP3A4 gene by the constitutive ..."
	AQ	Marks et al., Nature Rev., Vol. 1 (2001), pp. 194-202, "Histone deacetylases and cancer: causes and therapies"
	AR	Meinke et al., Curr. Med. Chem., Vol. 8 (2001), pp. 211-235, "Histone deacetylase: A target for antiproliferative and antiprotozoal agents"
/M.M./	AS	Raucy et al., J. Pharmacol. & Exper. Therapeutics, Vol. 303 (2002), pp. 412-423, "A cell-based reporter gene assay for determining induction of CYP3A4 ..."
	AT	Meinke et al., J. Med. Chem., Vol. 43 (2000), pp. 4919-4922, "Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase ..."
	AU	Samoucenti et al., J. Biol. Chem., Vol. 274 (1999), pp. 34940-34947, "Histone deacetylase inhibition selectively alters the activity and expression of cell cycle ..."
	AV	Cress et al., J. Cell. Physiol., Vol. 184 (2000), pp. 1-16, "Histone deacetylases, transcriptional control, and cancer"
/M.M./	AW	Nakano et al., J. Biol. Chem., Vol. 272 (1997), pp. 22199-22206, "Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites ..."
	AX	Han et al., J. Biol. Chem., Vol. 276 (2001), pp. 42084-42090, "Activation of p21-WAF1/Cip1 transcription through Sp1 sites ..."
/M.M./	AY	Drocourt et al., J. Biol. Chem., Vol. 277 (2002), pp. 25125-25132, "Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D ..."
	AZ	Sowa et al., Cancer Res., Vol. 59 (1999), pp. 4266-4270, "Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene ..."
	BA	Ju et al., Cancer Res., Vol. 63 (2003), pp. 2891-2897, "Histone deacetylase inhibitors activate p21-WAF1 expression via ATM"
	BB	Furumai et al., Cancer Res., Vol. 62 (2002), pp. 4916-4921, "FK228 (depsipeptide) as a natural prodrug that inhibits Class I ..."
	BC	Zlokarnik et al., Science, Vol. 279 (1998), pp. 84-88, "Quantitation of transcription and clonal selection of single living cells ..."
	BD	Fauston et al., Science, Vol. 272 (1996), pp. 408-411, "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p"

Examiner Signature	/Maria Marvich/	Date Considered	10/25/2008
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/582,621	
			Filing Date	June 12, 2006	
			First Named Inventor	Pallaoro et al.	
			Group Art Unit	--	
			Examiner Name	--	
Sheet	4	of	4	Attorney Docket Number	ITR0053YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	BE	Rishon et al., PNAS, Vol. 97 (2000), pp. 10014-10019, "Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation"
	BF	Meinke et al., Tetra. Letters, Vol. 41 (2000), pp. 7831-7835, "Synthesis of side chain modified apicidin derivatives: potent mechanism-based histone ..."
	BG	Colletti et al., Tetra. Letters, Vol. 41 (2000), pp. 7837-7841, "Design and synthesis of histone deacetylase inhibitors: the development of apicidin ..."
	BH	Colletti et al., Tetra. Letters, Vol. 41 (2000), pp. 7825-7829, "Tryptophan-replacement and indole-modified apicidins: synthesis of potent and selective ..."
	BI	Archer et al., PNAS, Vol. 95 (1998), pp. 6791-6796, "p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells"
	BJ	Xiao et al., J. Cell. Biochem., Vol. 73 (1999), pp. 291-302, "Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone ..."
	BK	Genbank No. U24170, "Human p21 (WAF1) gene, partial promoter sequence", submitted April 5, 1995
	BL	Genbank No. AF497972, "Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) gene, complete cds", submitted April 2, 2002
	BM	Genbank No. Z85996, "Human DNA sequence from clone RP3-431A14 on chromosome 6p21, complete sequence, submitted January 16, 2007
	BN	Perez et al., Proc. of the Am. Assoc. for Cancer Res., 93rd Annual Meeting, March 2002, Vol. 13, Abstract No. 3671, "Discovery and SAR of NVP-LAQ824, a novel histone deacetylase inhibitor with in vitro and in vivo antitumor activity"

duplicate references

Examiner Signature	/Maria Marvich/	Date Considered	10/25/2008
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006